Cell Therapy News

Perhaps no one has been better prepared to become a leader in the field of cancer cellular immunotherapy than Marcela V. Maus, MD, PhD.

Researchers have developed a genetically modified form of the immune-stimulating protein interleukin-7 that significantly enhanced chimeric antigen receptor T-cell therapy activity in preclinical testing.

Koen van Besien, MD, PhD, has been appointed chief of the division of hematology at University Hospitals Seidman Cancer Center.

Nearly 40% of patients who received chimeric antigen receptor T-cell therapy required hospitalization for disease- or treatment-related reasons in the year after infusion, results of a research letter in JAMA Oncology showed.

The use of broad-spectrum antibiotics in the month leading up to chimeric antigen receptor T-cell therapy led to poorer outcomes and increased treatment-related toxicities, study results showed.

An investigational chimeric antigen receptor T-cell therapy provided via multiple infusions induced a 100% overall response rate among adults with relapsed or refractory multiple myeloma, results from a pilot study showed.

Marco Davila, MD, PhD, has been appointed senior vice president and associate director for translational research at Roswell Park Comprehensive Cancer Center.

The FDA granted orphan drug designation to several therapies in development for oncology indications.

Crystal L. Mackall, MD, believes she has an "unusual pedigree" for someone in her position.

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.